نوع مقاله : Original Article(s)
نویسندگان
1 کارشناسی ارشد، مرکزتحقیقات سلولی مولکولی، گروه بیوشیمی بالینی، دانشکدهی پزشکی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران
2 استادیار، مرکزتحقیقات سلولی مولکولی، گروه بیوشیمی بالینی، دانشکدهی پزشکی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران
چکیده
تازه های تحقیق
سحر ساکی: Google Scholar
مهدی حاتمی: Google Scholar
اعظم خدری: Google Scholar
سمانه صالحی پور باورصاد: Google Scholar
کلیدواژهها
موضوعات
عنوان مقاله [English]
نویسندگان [English]
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Current treatment methods, such as chemotherapy and radiation therapy, can cause damage to patients' organs and occasionally lead to death. Etoposide (ETO), a widely used chemotherapeutic agent, has similar issues. Exosomes derived from mesenchymal stem cells represent a novel approach that may reduce side effects by targeted delivery of bioactive molecules to cancer cells.
Methods: HepG2 cancer cells were first cultured in a DMEM medium containing 10% fetal bovine serum (FBS) until reaching appropriate confluence. Then, the HepG2 cells were treated with 25 and 50 µM concentrations of exosomes for 24 hours. Subsequently, the expression levels of BAX and BCL-2 genes, ROS levels, and the apoptosis rate were measured.
Findings: Treatment of HepG2 cells with exosomes derived from mesenchymal stem cells led to an increase in BAX gene expression and a decrease in BCL-2 gene expression. Additionally, the levels of reactive oxygen species (ROS) and apoptosis rates were significantly higher compared to the control group, indicating a positive effect of exosomes in inducing programmed cell death.
Conclusion: Exosomes derived from MSCs were able to induce apoptosis in HepG2 cancer cells through the production of ROS. These findings suggest that exosomes can be utilized as a promising novel therapeutic approach in cancer treatment and offer strategies for developing safer and more effective cancer therapies.
کلیدواژهها [English]